Genomic Era Reaches Pediatric Oncology

Meir Rinde
Published: Tuesday, Sep 04, 2018
Rajen Mody, MBBS

Rajen Mody, MBBS

The relative rarity of pediatric cancers has hampered the work of uncovering their causes and developing new therapies, but efforts to expand the use of genomic and biomarker testing are beginning to provide new options for children and their families, as well as more information to help tailor therapeutic plans.

“By definition, any pediatric tumor is an orphan disease. Now all of sudden people are realizing that with these molecularly targeted agents, there’s a very, very small subgroup of patients who are going to have the marker, and they want to find the small populations,” said Julia L. Glade Bender, MD, vice chair of pediatric clinical research at Memorial Sloan Kettering Cancer Center in New York, New York. “If you’re looking for the needles in the haystacks, you need more haystacks.”

Figure. Targeted Therapies Explored in Pediatric MATCH Trial2


... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Practice Connections™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut AllergySep 28, 20191.0
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Publication Bottom Border
Border Publication
x